Excision Margins Don't Impact Melanoma Recurrence, Survival

This article originally appeared here.
Share this content:
Excision Margins Don't Impact Melanoma Recurrence, Survival
Excision Margins Don't Impact Melanoma Recurrence, Survival

MONDAY, April 11, 2016 (HealthDay News) -- Wider excision margins in thick cutaneous melanoma cases do not improve locoregional recurrence or melanoma-specific survival (MSS), according to research published online March 25 in Head & Neck.

Olivia Ruskin, M.B.B.S., from the Peter MacCallum Cancer Centre in Melbourne, Australia, and colleagues reviewed the records of 108 patients (median age, 71.1 years) treated at a single site for head and neck melanoma between 2002 and 2012 (median follow-up, 40 months). The authors sought to assess the impact of excision margins and sentinel lymph node status on locoregional recurrence and MSS.

The researchers found that the median Breslow thickness was 6.0 mm and locoregional recurrence happened in 27 percent of cases. There was no significant reduction in recurrence with margins ≥2 cm (P = 0.17), and there was no survival improvement with increasing margins (P = 0.58). Of the 59 patients (55 percent) who underwent sentinel node biopsy, 27 percent were positive. Patients who were sentinel lymph node-negative had a trend toward longer survival (P = 0.097).

"Wider margins do not significantly improve locoregional recurrence or MSS," the authors write. "Sentinel lymph node involvement reflects a poor prognosis."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »